Skip to main
DWTX

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics Inc. has a positive outlook due to its strategic licensing agreement with Serpin Pharma for global rights to SP16, aimed at treating cancer-related pain, which could significantly enhance revenue potential. The company's focus on developing innovative antiviral therapies to combat diseases linked to viral-induced abnormal immune responses positions it favorably within the biotechnology sector. Furthermore, with anticipated advancements in the SP16 clinical program and the possibility of forming partnerships for its development, Dogwood Therapeutics exhibits strong growth prospects, reflected in the recent increase in its share price target.

Bears say

Dogwood Therapeutics Inc., a development-stage biotechnology company, faces a negative outlook due to its reliance on advancing novel antiviral therapies, which inherently involves high-risk and uncertain development timelines. Despite a reported low dropout rate of 4.4% that may suggest patient satisfaction with its therapies, the company’s financial health remains a concern as it continues to operate without a proven product in the market, which may hinder revenue generation. Additionally, the combined approach of IMC-1 and IMC-2 against specific viral infections may not guarantee successful outcomes, further complicating its financial stability and growth potential.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.